Impact of Lanthanum Carbonate on Prognosis of Chronic Hemodialysis Patients: A Retrospective Cohort Study (Kawashima Study)

Therapeutic Apheresis and Dialysis

Volumn 20, Issue 2, 2016, Pages 142-148

  Tsuchida, Kenji ^a   Nagai, Kojiro ^b   Yokota, Narushi ^c   Minakuchi, Jun ^c   Kawashima, Shu ^c  

^a Kawashima Cardiovascular Clinic   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c Kawashima Hospital   (Japan)

Author keywords

Hemodialysis; Hyperphosphatemia; Lanthanum carbonate; Survival; Vascular calcification

Indexed keywords

ALBUMIN; CALCIUM; GAMMA GLUTAMYLTRANSFERASE; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHORUS; SODIUM; TRIACYLGLYCEROL; CHELATING AGENT; LANTHANUM;

ADULT; AGE DISTRIBUTION; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; ERYTHROCYTE COUNT; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK REDUCTION; SODIUM BLOOD LEVEL; SURVIVAL TIME; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; DISEASE COURSE; MIDDLE AGED; MORTALITY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; VASCULAR CALCIFICATION;

AGED; CARDIOVASCULAR DISEASES; CHELATING AGENTS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LANTHANUM; MALE; MIDDLE AGED; PHOSPHORUS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR CALCIFICATION;

EID: 84959508496     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12399     Document Type: Article

References (23)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:S112-9.
2. Nakai S, Hanafusa N, Masakane I et al. An overview of regular dialysis treatment in Japan (as of 31 December 2012). Ther Apher Dial 2014;18:535-602.
3. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000;35:S117-31.
4. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-53.
5. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;(113):S1-130.
6. Fukagawa M, Yokoyama K, Koiwa F et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 2013;17:247-88.
7. Nakai S, Akiba T, Kazama J et al. Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 2008;12:49-54.
8. Taniguchi M, Fukagawa M, Fujii N et al. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial 2013;17:221-8.
9. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17.
10. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
11. Cannata-Andia JB, Fernandez-Martin JL, Locatelli F et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 2013;84:998-1008.
12. Isakova T, Gutierrez OM, Chang Y et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009;20:388-96.
13. Lopes AA, Tong L, Thumma J et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012;60:90-101.
14. Jamal SA, Vandermeer B, Raggi P et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013;382:1268-77.
15. Rosenbaum P, Rubin D. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-24.
16. Wilson R, Zhang P, Smyth M, Pratt R. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Res Opin 2009;25:3021-8.
17. Komaba H, Kakuta T, Suzuki H, Hida M, Suga T, Fukagawa M. Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia. Nephrol Dial Transplant 2015;30:107-14.
18. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7.
19. Ohtake T, Kobayashi S, Oka M et al. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study. J Cardiovasc Pharmacol Ther 2013;18:439-46.
20. Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology (Carlton) 2011;16:290-8.
21. Wada K, Wada Y. Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial. Ther Apher Dial 2014;18:353-60.
22. Shinaberger CS, Greenland S, Kopple JD et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr 2008;88:1511-8.
23. Landmark Study (NCT01578200) https://clinicaltrials.gov/ct2/show/NCT01578200